Literature DB >> 12659781

[Crohn's disease and pregnancy. About 34 cases. Review of the literature].

F Sergent1, E Verspyck, L Marpeau.   

Abstract

OBJECTIVE: To define the optimal conditions of pregnancy in patients affected by Crohn's disease. MATERIAL AND
METHOD: Retrospective study of 25 patients affected by Crohn's disease, followed during eight years at Rouen's University Hospital.
RESULTS: Twenty patients added up 34 pregnancies. Seventeen patients at least had a child, adding up 26 livebirths. Among the 17 pregnancies beginning with an active Crohn's disease, this proved to be still active in 16 cases. Among the eight interrupted pregnancies, six had an active disease. Out of the five menaces of preterm delivery stopped or not, four were in push. Eight neonatal hypotrophies were connected to a push. DISCUSSION AND
CONCLUSIONS: From a confrontation between the data of the literature and our experience, it emerges the following essential points: when Crohn's disease is quiescent, it does not affect the pregnancy, except a moderate fetal hypotrophy. When the disease is active, the risk of abortion and prematurity increases. There is no influence of the pregnancy on Crohn's disease, when pregnancy arises during a period of quiescence of the disease. Two thirds of the pregnancies of these women take place without new push of their disease. During pregnancy, there is no contraindication as far as the usual treatments of Crohn's disease are concerned, with a limitation however for the use of immunosuppressants.

Entities:  

Mesh:

Year:  2003        PMID: 12659781     DOI: 10.1016/s1297-9589(02)00003-6

Source DB:  PubMed          Journal:  Gynecol Obstet Fertil        ISSN: 1297-9589


  1 in total

1.  First-in-Human Case Study: Pregnancy in Women With Crohn's Perianal Fistula Treated With Adipose-Derived Stem Cells: A Safety Study.

Authors:  Raquel Sanz-Baro; Mariano García-Arranz; Hector Guadalajara; Paloma de la Quintana; Maria Dolores Herreros; Damián García-Olmo
Journal:  Stem Cells Transl Med       Date:  2015-04-29       Impact factor: 6.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.